Immunochromatographic SARS-CoV-2 IgG antibody assay: a cross-sectional study conducted at Wakayama Medical University in Japan
Iwabuchi, S.; Katsuda, M.; Koizumi, Y.; Hatai, M.; Kojima, M.; Tokudome, N.; Tamura, S.; Nishio, M.; Kondo, T.; Hironishi, M.; Kakutani, C.; Yamaue, H.; Hashimoto, S.
Show abstract
Asymptomatic patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection must be quickly identified and isolated to prevent the spread of the virus. The number of asymptomatic healthy people is completely unknown because they remain untested. Detection of specific SARS-CoV-2 antibodies has been widely accepted as a diagnostic test, and an immunochromatographic test, which is simpler and relatively cheaper than other methods, is becoming the gold standard for identifying healthy people who had been infected with SARS-CoV-2 in the past. In this study, 1,528 volunteers who worked at a particular hospital were subjected to an immunochromatographic IgG test for SARS-CoV-2 to determine the ratio of asymptomatic people. Only 12 volunteers (0.79%) were IgG+, with no significant background differences in the sex, age, profession, experiences of working at the emergency department or caring for coronavirus disease 2019 patients. If this IgG+ ratio was to be extrapolated to Wakayama citys population, 2,780 out of 3,54,063 people may be asymptomatic for SARS-CoV-2. The results imply that anyone may get infected with SARS-CoV-2 but remain asymptomatic.
Matching journals
The top 1 journal accounts for 50% of the predicted probability mass.
Similar papers in this journal
- Evaluation and clinical implications of the time to a positive results of antigen testing for SARS-CoV-2 97%
- Diagnostic performance of a novel digital immunoassay (RapidTesta SARS-CoV-2): a prospective observational study with 1,127 nasopharyngeal samples 96%
- Prospective analytical performance evaluation of the QuickNavi™-COVID19 Ag for asymptomatic individuals 96%
Similar papers in this journal
- Evaluation of anti-SARS-CoV-2 antibody testing in asymptomatic or mild COVID-19 patients in outbreak on a cruise ship 97%
- SARS-CoV-2 RNA shedding in recovered COVID-19 cases and the presence of antibodies against SARS-CoV-2 in recovered COVID-19 cases and close contacts 96%
- Validation of a new automated chemiluminescent anti-SARS-CoV-2 IgM and IgG antibody assay system detecting both N and S proteins in Japan 96%
Similar papers in this journal
- Validation and Performance Comparison of Three SARS-CoV-2 Antibody Assays 96%
- Viral loads and profile of the patients infected with SARS-CoV-2 Delta, Alpha or R.1 variants in Tokyo 96%
- Clinical evaluation of an automated, rapid mariPOC ® antigen test in screening of symptomatics and asymptomatics for SARS-CoV-2 infections 95%
Similar papers in this journal
- Performance of SARS-CoV-2 rapid antigen test compared with real-time RT-PCR in asymptomatic individuals 96%
- Performance evaluation of novel fluorescent-based lateral immune flow assay (LIFA) for rapid detection and quantitation of total anti-SARS-CoV-2 S-RBD binding antibodies in infected individuals 95%
- Live poultry feeding and trading network and the transmission of avian influenza A(H5N6) virus in a large city in China, 2014-2015 94%
Similar papers in this journal
- Performance of a point of care test for detecting IgM and IgG antibodies against SARS-CoV-2 and seroprevalence in blood donors and health care workers in Panama 96%
- SARS-CoV-2 testing in the Slovak Republic from March 2020 to September 2022 – summary of the pandemic trends 94%
- SARS-CoV-2 antibody prevalence and symptoms in a local Austrian population 94%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.